

**SnoN Antibody**

**Orders:** 877-616-CELL (2355)  
orders@cellsignal.com

**Support:** 877-678-TECH (8324)

**Web:** info@cellsignal.com  
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

**For Research Use Only. Not for Use in Diagnostic Procedures.**

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IF-IC	H	Endogenous	80	Rabbit	#P12757	6498

**Product Usage Information****Application**

Western Blotting  
Immunofluorescence (Immunocytochemistry)

**Dilution**

1:1000  
1:50

**Storage**

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody.

**Specificity/Sensitivity**

SnoN Antibody detects endogenous levels of total SnoN protein.

**Species predicted to react based on 100% sequence homology**

Monkey

**Source / Purification**

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser431 of human SnoN protein. Antibodies were purified by protein A and peptide affinity chromatography.

**Background**

Transforming growth factor- $\beta$  (TGF- $\beta$ ) superfamily members are critical regulators of cell proliferation and differentiation, developmental patterning and morphogenesis and disease pathogenesis (1-3). Upon stimulation by TGF- $\beta$ , activated receptors phosphorylate Smad2 and Smad3, resulting in their translocation to the nucleus, association with Smad4 and transcriptional regulation of target genes (4). Ski and SnoN are related oncoproteins originally discovered based on homology to v-Ski, the transforming protein of the Sloan-Kettering virus (5). They regulate TGF- $\beta$  signaling by binding to Smad2 and Smad4 and repressing their ability to activate transcription (6). Following TGF- $\beta$  stimulation, SnoN is rapidly degraded by the ubiquitin proteasome pathway providing negative feedback regulation (6-9). Overexpression of SnoN and Ski can transform avian fibroblasts and induce muscle differentiation (10). Mice heterozygous for SnoN and Ski display increased susceptibility to tumorigenesis (11,12). Interestingly, elevated expression of Ski and SnoN has been observed in many tumors and may serve as important prognostic markers (13,14). Taken together, these studies suggest possible dual functions of these proteins at different stages of tumorigenesis (15).

**Background References**

1. Massagué, J. et al. (2000) *Cell* 103, 295-309.
2. de Caestecker, M.P. et al. (2000) *J. Natl. Cancer Inst.* 92, 1388-1402.
3. Derynck, R. et al. (2001) *Nat. Genet.* 29, 117-129.
4. Miyazono, K. et al. (2000) *Adv. Immunol.* 75, 115-157.
5. Nomura, N. et al. (1989) *Nucleic Acids Res.* 17, 5489-5500.
6. Stroschein, S.L. et al. (1999) *Science* 286, 771-774.
7. Bonni, S. et al. (2001) *Nat. Cell Biol.* 3, 587-595.
8. Stroschein, S.L. et al. (2001) *Genes Dev.* 15, 2822-2836.
9. Wan, Y. et al. (2001) *Mol. Cell* 8, 1027-1039.
10. Boyer, P.L. et al. (1993) *Oncogene* 8, 457-466.
11. Shinagawa, T. et al. (2001) *Oncogene* 20, 8100-8108.
12. Shinagawa, T. et al. (2000) *EMBO J.* 19, 2280-2291.
13. Zhang, F. et al. (2003) *Cancer Res.* 63, 5005-5010.
14. Buess, M. et al. (2004) *Neoplasia* 6, 207-212.
15. Zhu, Q. et al. (2007) *Mol. Cell. Biol.* 27, 324-339.

**Species Reactivity**

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

**Western Blot Buffer**

**IMPORTANT:** For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

**Applications Key**

**W:** Western Blotting **IF-IC:** Immunofluorescence (Immunocytochemistry)

**Cross-Reactivity Key**

**H:** Human

**Trademarks and Patents**

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit [cellsignal.com/trademarks](http://cellsignal.com/trademarks) for more information.

**Limited Uses**

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.